Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stromal cells for drug-resistant pediatric juvenile idiopathic arthritis
NL-OMON39754Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in juvenile idiopathic arthritis (JIA), sponsored by University Medical Center Utrecht. Primary endpoint: Safety: adverse events before and after infusion. Started Oct 2014; status: active, not recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON39754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39754.